Bao-Fang Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bao-Fang Zhang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Haiyang Li
Department of Hepatobiliary Surgery, Key Laboratory of Hepatobiliary and Pancreatic Diseases Treatment and Bioinformatics Research, The Affiliated Hospital of Guizhou Medical University, Guizhou Medical University, China
4 shared publications Huan Wu
Department of Infectious Diseases, The Affiliated Hospital of Guizhou Medical University, Guiyang City, China
3 shared publicationsLong Wu
Department of Anus and Intestinal Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, China
3 shared publicationsCan Li
Department of Infectious Diseases, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
1 shared publication- Can Li
Department of Infectious Diseases, The Affiliated Hospital of Guizhou Medical University, Guiyang 550008, China
1 shared publication Fei Huang
Department of Anus and Intestinal Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
1 shared publication
Latest Publications
- Open Access
- 5 April 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (4) , 829
α-Hederin Alleviates Endoplasmic Reticulum Stress by Upregulating TRIM38 Expression, Thereby Inhibiting Hepatic Stellate Cell Activation and Liver Fibrosis
Objectives: This study aims to investigate the potential molecular mechanisms by which α-hederin modulates HSC activation to alleviate liver fibrosis. Methods: An in vitro model of liver fibrosis was established by inducing LX-2 cells with TGF-β1. These cells were then treated with α-hederin (10 μg/mL) before undergoing phenotypic analysis and molecular-level detection. A mouse model of liver fibrosis induced by CCl4 was established in vivo to further evaluate the expression levels of fibrosis markers, including TRIM38. Results: In TGF-β1-induced liver fibrosis in LX-2 cells, α-hederin treatment significantly inhibited HSCs activation, as evidenced by down-regulation of α-SMA and suppressed proliferation capacity. At the same time, α-hederin significantly reduced the levels of COL1A1, COL3A1, fibronectin, and MMP-2. Transcriptome sequencing analysis revealed that α-hederin treatment significantly upregulated TRIM38 expression. Differentially expressed genes (DEGs) were significantly enriched in endoplasmic reticulum stress-related pathways. TRIM38 up-regulation inhibits HSC activation and proliferation, reducing the expression of ERS marker proteins (GRP78, p-PERK, and CHOP); Co-IP experiments further confirmed that TRIM38 and GRP78 interact directly. Further rescue experiments demonstrated that TRIM38 knockdown significantly attenuated the inhibitory effects of α-hederin on these processes. In a CCl4-induced mouse model of liver fibrosis, α-hederin (4 mg/kg) significantly reduced the liver index and serum ALT and AST levels, improved histopathological damage to the liver, upregulated TRIM38 expression in liver tissue, and inhibited the endoplasmic reticulum stress response (ERS). Conclusions: α-hederin exerts its anti-fibrotic effect by upregulating TRIM38, thereby alleviating endoplasmic reticulum stress and ultimately inhibiting the activation and proliferation of HSCs.
- 5 April 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (4) , 829
Open Accessα-Hederin Alleviates Endoplasmic Reticulum Stress by Upregulating TRIM38 Expression, Thereby Inhibiting Hepatic Stellate Cell Activation and Liver Fibrosis
Objectives: This study aims to investigate the potential molecular mechanisms by which α-hederin modulates HSC activation to alleviate liver fibrosis. Methods: An in vitro model of liver fibrosis was established by inducing LX-2 cells with TGF-β1. These cells were then treated with α-hederin (10 μg/mL) before undergoing phenotypic analysis and molecular-level detection. A mouse model of liver fibrosis induced by CCl4 was established in vivo to further evaluate the expression levels of fibrosis markers, including TRIM38. Results: In TGF-β1-induced liver fibrosis in LX-2 cells, α-hederin treatment significantly inhibited HSCs activation, as evidenced by down-regulation of α-SMA and suppressed proliferation capacity. At the same time, α-hederin significantly reduced the levels of COL1A1, COL3A1, fibronectin, and MMP-2. Transcriptome sequencing analysis revealed that α-hederin treatment significantly upregulated TRIM38 expression. Differentially expressed genes (DEGs) were significantly enriched in endoplasmic reticulum stress-related pathways. TRIM38 up-regulation inhibits HSC activation and proliferation, reducing the expression of ERS marker proteins (GRP78, p-PERK, and CHOP); Co-IP experiments further confirmed that TRIM38 and GRP78 interact directly. Further rescue experiments demonstrated that TRIM38 knockdown significantly attenuated the inhibitory effects of α-hederin on these processes. In a CCl4-induced mouse model of liver fibrosis, α-hederin (4 mg/kg) significantly reduced the liver index and serum ALT and AST levels, improved histopathological damage to the liver, upregulated TRIM38 expression in liver tissue, and inhibited the endoplasmic reticulum stress response (ERS). Conclusions: α-hederin exerts its anti-fibrotic effect by upregulating TRIM38, thereby alleviating endoplasmic reticulum stress and ultimately inhibiting the activation and proliferation of HSCs.
- Open Access
- 28 March 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1-13
Association between lactate-to-albumin ratio and mortality in hepatic failure: a retrospective cohort study
Background: Liver failure has a high mortality rate, and currently, there is no convenient risk predictor. The lactate-to-albumin ratio (LAR) has emerged as a promising predictor in various critical illnesses. However, its potential role in predicting all-cause mortality in patients with liver failure remains unexplored. Therefore, this study aims to investigate the correlation between LAR and all-cause mortality in patients suffering from liver failure. Methods: We retrospectively analyzed data from patients with liver failure who were admitted to the intensive care unit (ICU) between 2008 and 2019, which were gathered from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. LAR was calculated from the ratio obtained from the first measurement taken within 24 h of admission. The optimal LAR threshold was determined using the Youden index. With LAR categorized into low, middle, and high groups based on tertiles, Kaplan - Meier analysis was employed to compare mortality risks among three patient groups. Multivariate Cox proportional hazards regression models were utilized to evaluate the association between LAR and all-cause mortality in hepatic failure patients within hospital admission. Additionally, receiver operating characteristic (ROC) and smoothing curve analysis were used to assess the predictive ability, sensitivity, and specificity of LAR for all-cause mortality in patients with liver failure, and the area under the curve (AUC) was calculated. A smooth curve fitting approach and threshold effect analysis were employed to detect the potentially non-linear relationship between the LAR and the risk of all-cause mortality in patients with hepatic failure. Finally, subgroup analyses were performed to assess the relationship between LAR and prognosis across different types of liver failure. Results: A total of 902 patients with hepatic failure were included in this study. They were divided into survivors group (611 patients) and non-survivors group (291 patients) according to whether they survived during hospitalization, and the mortality rate of patients was 32.26%. The Kaplan-Meier survival curves illustrating patients in hepatic failure with elevated LAR showed a significantly heightened risk of in-hospital mortality (P < 0.001). We identified a non-linear relationship between LAR and the risk of hospital mortality after adjusting for potential confounders and the inflection point of LAR to be 1.33. LAR was shown to be an independent predictor of all-cause mortality within hospitalization in patients with hepatic failure by multivariate COX regression analysis (HR, 1.66; 95% CI, 1.35–2.05; P < 0.0001). The optimal cutoff value for separating the survival and death groups according to ROC was found to be 0.97. The AUC value for LAR was 0.755 (95% CI: 0.721, 0.789), which was higher than that for arterial blood lactate (AUC = 0.725) and serum albumin (AUC = 0.680) alone. It was not inferior even when compared to MELD (AUC = 0.677). Conclusion: LAR has demonstrated good predictive value for all-cause mortality among liver failure patients in our retrospective study.
- 28 March 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1-13
Open AccessAssociation between lactate-to-albumin ratio and mortality in hepatic failure: a retrospective cohort study
Background: Liver failure has a high mortality rate, and currently, there is no convenient risk predictor. The lactate-to-albumin ratio (LAR) has emerged as a promising predictor in various critical illnesses. However, its potential role in predicting all-cause mortality in patients with liver failure remains unexplored. Therefore, this study aims to investigate the correlation between LAR and all-cause mortality in patients suffering from liver failure. Methods: We retrospectively analyzed data from patients with liver failure who were admitted to the intensive care unit (ICU) between 2008 and 2019, which were gathered from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. LAR was calculated from the ratio obtained from the first measurement taken within 24 h of admission. The optimal LAR threshold was determined using the Youden index. With LAR categorized into low, middle, and high groups based on tertiles, Kaplan - Meier analysis was employed to compare mortality risks among three patient groups. Multivariate Cox proportional hazards regression models were utilized to evaluate the association between LAR and all-cause mortality in hepatic failure patients within hospital admission. Additionally, receiver operating characteristic (ROC) and smoothing curve analysis were used to assess the predictive ability, sensitivity, and specificity of LAR for all-cause mortality in patients with liver failure, and the area under the curve (AUC) was calculated. A smooth curve fitting approach and threshold effect analysis were employed to detect the potentially non-linear relationship between the LAR and the risk of all-cause mortality in patients with hepatic failure. Finally, subgroup analyses were performed to assess the relationship between LAR and prognosis across different types of liver failure. Results: A total of 902 patients with hepatic failure were included in this study. They were divided into survivors group (611 patients) and non-survivors group (291 patients) according to whether they survived during hospitalization, and the mortality rate of patients was 32.26%. The Kaplan-Meier survival curves illustrating patients in hepatic failure with elevated LAR showed a significantly heightened risk of in-hospital mortality (P < 0.001). We identified a non-linear relationship between LAR and the risk of hospital mortality after adjusting for potential confounders and the inflection point of LAR to be 1.33. LAR was shown to be an independent predictor of all-cause mortality within hospitalization in patients with hepatic failure by multivariate COX regression analysis (HR, 1.66; 95% CI, 1.35–2.05; P < 0.0001). The optimal cutoff value for separating the survival and death groups according to ROC was found to be 0.97. The AUC value for LAR was 0.755 (95% CI: 0.721, 0.789), which was higher than that for arterial blood lactate (AUC = 0.725) and serum albumin (AUC = 0.680) alone. It was not inferior even when compared to MELD (AUC = 0.677). Conclusion: LAR has demonstrated good predictive value for all-cause mortality among liver failure patients in our retrospective study.
- Open Access
- 19 August 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 48 (1) , 906-907
Primary undifferentiated sarcoma of the transverse colon in a young female patient
- 19 August 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 48 (1) , 906-907
Open AccessPrimary undifferentiated sarcoma of the transverse colon in a young female patient
- Open Access
- 31 July 2024
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 11, 1292954
No causal relationship between serum vitamin D levels and alcoholic liver disease: a two-sample bidirectional Mendelian randomization study
Background: Numerous observational studies have presented an association between Vitamin D (VD) and Alcoholic Liver Disease (ALD). However, sufficient evidence from Randomized Controlled Trials (RCTs) substantiating this correlation is scarce, thus leaving the causality of this relationship ambiguous. To overcome the shortcomings of traditional observational studies, we performed a two-sample bidirectional Mendelian randomization (MR) analysis to ascertain the causal relationship between VD and ALD.Methods: We utilized summary statistics datasets from Genome-Wide Association Studies (GWAS) for VD and ALD. We selected genetic instruments that measure circulating VD levels (n = 64,979), and retrieved ALD statistics from GWASs, inclusive of 1,416 cases and 217,376 healthy controls, while excluding chronic liver diseases such as nonalcoholic fatty liver disease, toxic liver disease, and viral hepatitis. Subsequent, MR analyses were performed to obtain effect estimates using inverse variance weighted (IVW) random effect models. Cochran’s Q statistic and MR-Egger regression intercept analyses were used to assess pleiotropy. Sensitivity analyses using the MR Egger, weighted median, simple mode, and weighted mode methods were also performed. Leave-one-out analysis was used to identify SNPs with potential effect. Reverse MR analysis was also performed.Results: In IVW, our MR analysis incorporated 21 independent SNPs, circulating VD levels had no causal effect on ALD [OR = 0.624 (0.336–1.160), p = 0.136] and ALD had no causal effect on circulating VD [OR = 0.997 (0.986–1.008), p = 0.555]. No heterogeneity or pleiotropy was observed (p > 0.05). Other MR methods also agreed with IVW results.Conclusion: This study provides the causal relationship between genetically predicted circulating Vitamin D levels and ALD and provides new insights into the genetics of ALD.
- 31 July 2024
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 11, 1292954
Open AccessNo causal relationship between serum vitamin D levels and alcoholic liver disease: a two-sample bidirectional Mendelian randomization study
Background: Numerous observational studies have presented an association between Vitamin D (VD) and Alcoholic Liver Disease (ALD). However, sufficient evidence from Randomized Controlled Trials (RCTs) substantiating this correlation is scarce, thus leaving the causality of this relationship ambiguous. To overcome the shortcomings of traditional observational studies, we performed a two-sample bidirectional Mendelian randomization (MR) analysis to ascertain the causal relationship between VD and ALD.Methods: We utilized summary statistics datasets from Genome-Wide Association Studies (GWAS) for VD and ALD. We selected genetic instruments that measure circulating VD levels (n = 64,979), and retrieved ALD statistics from GWASs, inclusive of 1,416 cases and 217,376 healthy controls, while excluding chronic liver diseases such as nonalcoholic fatty liver disease, toxic liver disease, and viral hepatitis. Subsequent, MR analyses were performed to obtain effect estimates using inverse variance weighted (IVW) random effect models. Cochran’s Q statistic and MR-Egger regression intercept analyses were used to assess pleiotropy. Sensitivity analyses using the MR Egger, weighted median, simple mode, and weighted mode methods were also performed. Leave-one-out analysis was used to identify SNPs with potential effect. Reverse MR analysis was also performed.Results: In IVW, our MR analysis incorporated 21 independent SNPs, circulating VD levels had no causal effect on ALD [OR = 0.624 (0.336–1.160), p = 0.136] and ALD had no causal effect on circulating VD [OR = 0.997 (0.986–1.008), p = 0.555]. No heterogeneity or pleiotropy was observed (p > 0.05). Other MR methods also agreed with IVW results.Conclusion: This study provides the causal relationship between genetically predicted circulating Vitamin D levels and ALD and provides new insights into the genetics of ALD.
- Open Access
- 16 November 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1282066
Causal association between constipation and risk of colorectal cancer: a bidirectional two-sample Mendelian randomization study
Background: Colorectal cancer (CRC) is a globally significant health concern, necessitating effective preventive strategies through identifying modifiable risk factors. Constipation, characterized by infrequent bowel movements or difficulty passing stools, has been proposed as a potential CRC risk factor. However, establishing causal links between constipation and CRC remains challenging due to observational study limitations.Methods: Mendelian randomization (MR) utilizes genetic variants as instrumental variables, capitalizing on genetically determined variation to assess causal relationships. In this dual-sample bidirectional MR study, we extracted genetic data from independent cohorts with CRC (Include colon cancer and rectal cancer) and constipation cases. Genome-wide association studies (GWAS) identified constipation and CRC-associated genetic variants used as instruments to infer causality. The bidirectional MR analysis evaluated constipation’s impact on CRC risk and the possibility of reverse causation.Results: Employing bidirectional MR, we explored the causal relationship between constipation and CRC using publicly available GWAS data. Analysis of constipation’s effect on CRC identified 26 significant SNPs, all with strong instrumental validity. IVW-random effect analysis suggested a potential causal link [OR = 1.002(1.000, 1.004); P = 0.023], although alternative MR approaches were inconclusive. Investigating CRC’s impact on constipation, 28 significant SNPs were identified, yet IVW analyses found no causal effect [OR = 0.137(0.007, 2.824); P = 0.198]. Other MR methods also yielded no significant causal association. We analyzed constipation separately from colon and rectal cancer using the same methodology in both directions, and no causal relationship was obtained.Conclusion: Our bidirectional MR study suggests a potential constipation-CRC link, with mixed MR approach outcomes. Limited evidence supports constipation causing CRC. Reliable instruments, minimal heterogeneity, and robust analyses bolster these findings, enriching understanding. Future research should explore additional factors to enhance comprehension and clinical implications.
- 16 November 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1282066
Open AccessCausal association between constipation and risk of colorectal cancer: a bidirectional two-sample Mendelian randomization study
Background: Colorectal cancer (CRC) is a globally significant health concern, necessitating effective preventive strategies through identifying modifiable risk factors. Constipation, characterized by infrequent bowel movements or difficulty passing stools, has been proposed as a potential CRC risk factor. However, establishing causal links between constipation and CRC remains challenging due to observational study limitations.Methods: Mendelian randomization (MR) utilizes genetic variants as instrumental variables, capitalizing on genetically determined variation to assess causal relationships. In this dual-sample bidirectional MR study, we extracted genetic data from independent cohorts with CRC (Include colon cancer and rectal cancer) and constipation cases. Genome-wide association studies (GWAS) identified constipation and CRC-associated genetic variants used as instruments to infer causality. The bidirectional MR analysis evaluated constipation’s impact on CRC risk and the possibility of reverse causation.Results: Employing bidirectional MR, we explored the causal relationship between constipation and CRC using publicly available GWAS data. Analysis of constipation’s effect on CRC identified 26 significant SNPs, all with strong instrumental validity. IVW-random effect analysis suggested a potential causal link [OR = 1.002(1.000, 1.004); P = 0.023], although alternative MR approaches were inconclusive. Investigating CRC’s impact on constipation, 28 significant SNPs were identified, yet IVW analyses found no causal effect [OR = 0.137(0.007, 2.824); P = 0.198]. Other MR methods also yielded no significant causal association. We analyzed constipation separately from colon and rectal cancer using the same methodology in both directions, and no causal relationship was obtained.Conclusion: Our bidirectional MR study suggests a potential constipation-CRC link, with mixed MR approach outcomes. Limited evidence supports constipation causing CRC. Reliable instruments, minimal heterogeneity, and robust analyses bolster these findings, enriching understanding. Future research should explore additional factors to enhance comprehension and clinical implications.